AngElle Bioengineering ApS: Financial statements 2025
CVR: 43155881
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
AngElle Bioengineering ApS (CVR 43155881) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -58,328 compared with DKK 38,363 the year before. Equity in the 2025 report amounted to DKK 82,579. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -58,328
- Equity
- DKK 82,579
- Total Assets
- DKK 82,579
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 0 | 0 | -58 t. | 83 t. | - |
| 2024 | 45 t. | 38 t. | 38 t. | 141 t. | - |
| 2023 | 0 | -1 t. | -1 t. | 103 t. | - |
Official annual report
How creditworthy is AngElle Bioengineering ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
AngElle Bioengineering ApS has published its annual report for 2024. Revenue came to DKK 44,631, and the net result was DKK 38,363.
About AngElle Bioengineering ApS
AngElle Bioengineering ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2022. The company is registered under the industry Anden teknisk rådgivning. The management consists of Irini Angelidaki. The company is owned by Irini Angelidaki. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -58,328 compared with DKK 38,363 the year before. Equity in the 2025 report amounted to DKK 82,579.